← Patent-cliff monitor small molecule ZYNRELEF KIT BUPIVACAINE; MELOXICAM
Loss of exclusivity April 2036 latest FDA-listed patent expiry
Drug detail Brand name ZYNRELEF KIT Active ingredient BUPIVACAINE; MELOXICAM Strength 60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML) Dosage form SOLUTION, EXTENDED RELEASE Route PERIARTICULAR Modality Small molecule FDA approval May 2021 Marketing status DISCN
Listed patents Patent Expires Type 11844837 April 2036 use U-3417 9694079 April 2035 product 9801945 April 2035 product 10213510 April 2035 product 10980886 April 2035 product 10632199 April 2035 product 10898575 April 2035 product 11083797 April 2035 product 11083730 April 2035 product 11413350 April 2035 use U-3417 10098957 April 2035 use U-3118 9913909 March 2034 use U-3118 11253504 March 2034 use U-3118 9592227 March 2034 product 9744163 March 2034 product 10398686 March 2034 product
Regulatory exclusivity Code Expires I-933 January 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.